Applying trial evidence back to the patient

Archives of Dermatology

Volumn 139, Issue 9, 2003, Pages 1195-1200

  Williams, Hywel C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; SILDENAFIL; STEROID;

ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL INFORMATICS; MEDICAL INFORMATION; METHODOLOGY; OUTCOMES RESEARCH; PATIENT; PATIENT COMPLIANCE; PATIENT INFORMATION; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK ASSESSMENT;

DERMATOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT CARE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 0141596230     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.9.1195     Document Type: Review

References (29)

1. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet. 1999;353:743-746.
2. Eypasch E. The individual patient and evidence-based medicine: a conflict? Langenbecks Arch Surg. 1999;384:417-422.
3. Williams H. Dowling Oration 2001: evidence-based dermatology - a bridge too far? Clin Exp Dermatol. 2001;26:714-724.
4. Dans AL, Dans LF, Guyatt GH, Richardson S. Users' guides to the medical literature, XIV: how to decide on the applicability of clinical trial results to your patient. JAMA. 1998;279:545-549.
5. Li Wan Po A. Dictionary of Evidence-Based Medicine. Oxford, England: Radcliffe Medical Press; 1998:52.
6. Roberts RJ, Casey D, Morgan DA, Petrovic M. Comparison of wet combing with malathion for treatment of head lice in the UK: a pragmatic randomised controlled trial. Lancet. 2000;356:540-544.
7. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology. 1999;54:1073-1077.
8. Nikles CJ, Glasziou PP, Del Mar CB, Duggan CM, Mitchell G. N of 1 trials: practical tools for medication management Aust Fam Physician. 2000;29:1108-1112.
9. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol. 2001;52(suppl 1):75S-87S.
10. Bakan D. The general and the aggregate: a methodological distinction. Percept Mot Skills. 1955;5:211-212.
11. Straus SE, McAlister FA. Evidence-based medicine: a commentary on common criticisms. CMAJ. 2000;163:837-841.
12. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4:1-191.
13. Charman C, Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol. 2000;136:763-769.
14. Olsen EA. Topical minoxidil in the treatment of androgenetic alopecia in women. Cutis. 1991;48:243-248.
15. Charman C, Chambers C, Williams HC. Measuring atopic dermatitis severity in randomised controlled clinical trials: what exactly are we measuring? J Invest Dermatol. in press.
16. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. Br J Psychiatry. 2000;176:249-252.
17. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
18. Devereaux PJ, Anderson DJ, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulaton in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218-1222.
19. Hollis S, Campbell F. What is meant by intention to treat analysis? survey of published randomised controlled trials. BMJ. 1999;319:670-674.
20. Eypasch E, Lefering R, Kum OK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ. 1995;311:619-620.
21. Levine M, Whelan T. Decision-making process - communicating risk/benefits: is there an ideal technique? J Natl Cancer Inst Monogr. 2001;30:143-145.
22. Thornton JG, Lilford RJ, Johnson N. Decision analysis in medicine. BMJ. 1992;304:1099-1103.
23. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Cost-effectiveness analysis of topical calcipotriol versus short-contact dithranol in the treatment of mild to moderate plaque psoriasis. Pharmacoeconomics. 2000;18:469-476.
24. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature, XX: integrating research evidence with the care of the individual patient. JAMA. 2000;283:2829-2836.
25. Gibbs S. Losing touch with the healing art: dermatology and the decline of pastoral doctoring. J Am Acad Dermatol. 2000;43:875-878.
26. Cotterill JA. Dermatological games. Br J Dermatol. 1981;105:311-320.
27. Johnson SR, Dunn BK, Anthony M. Defining benefits and risks for SERMs in clinical trials and clinical practice. Ann N Y Acad Sci. 2001;949:304-314.
28. Williams HC, Monk B. Creeping eruption stopped in its tracks by albendazole. Clin Exp Derm. 1989;14:355-356.
29. Caumes E, Carriere J, Datry A, Gaxotte P, Danis M, Gentilini M. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg. 1993;49:641-644.